Oxford, UK – The Shingrix vaccine, initially hailed for its efficacy against the painful viral infection shingles, is increasingly drawing attention for potential health benefits far beyond its primary indication. Two years after groundbreaking research hinted at a link between the newer recombinant vaccine and reduced dementia rates, the same pioneering team at the University of Oxford has now uncovered another compelling association: a decreased risk of heart disease in vaccinated individuals. This latest finding, published Wednesday in Nature Medicine, significantly bolsters the vaccine’s profile, suggesting it could play an unexpected, multifaceted role in public health, potentially safeguarding both the brain and the cardiovascular system.
n
For years, preventing shingles – a debilitating flare-up of the chickenpox virus that can cause severe nerve pain – has been the sole focus of vaccination efforts. However, a growing body of evidence, including earlier "signals" of cardiovascular benefits, has prompted scientists to investigate whether Shingrix offers broader protection. This new study provides some of the most robust observational data to date, painting a picture of a vaccine whose therapeutic reach may extend into the realm of chronic disease prevention.
n
Unveiling a Dual Defense: The Latest Breakthroughs
n
The journey to understanding Shingrix’s potential broader benefits began with a pivotal observation two years ago.
n
Initial Dementia Link Recalled
n
In 2022, the Oxford research team made headlines by reporting a significant association between receiving the Shingrix vaccine and a lower incidence of dementia. This discovery sparked considerable excitement within the scientific community, as it suggested a novel pathway for preventing neurodegenerative diseases, which currently lack effective preventative strategies. The initial findings, published in a prominent scientific journal, positioned Shingrix not just as a defense against a viral infection, but as a potential tool in the fight against one of the most challenging health crises of our time. The revelation hinted that preventing the herpes zoster virus might mitigate systemic inflammation or other biological processes implicated in cognitive decline.
n
New Horizons: Cardiovascular Health
n
Building on the momentum of their previous work, the Oxford researchers turned their attention to cardiovascular health. Prior to this study, there had been tantalizing but inconclusive indications that individuals vaccinated against shingles, particularly with the newer recombinant vaccine, might experience a reduced risk of heart attacks, strokes, and heart failure. These earlier observations, while intriguing, were often limited by methodological challenges inherent in observational studies, primarily the difficulty of definitively proving cause and effect.
n
The current study, however, takes a significant step forward. By leveraging a unique "natural experiment," the researchers were able to mitigate some of these challenges, providing a more compelling case for Shingrix’s cardioprotective effects. The findings suggest that Shingrix is associated with a noticeable reduction in the overall burden of cardiovascular diseases, encompassing a spectrum of conditions that collectively represent a leading cause of mortality and morbidity worldwide. This latest discovery transforms the narrative around Shingrix from a single-purpose vaccine to a potential multi-benefit agent, sparking renewed interest in its full therapeutic potential.
n
The Research Journey: Addressing the "What Ifs"
n
Observational studies, while crucial for identifying potential associations, are inherently susceptible to confounding factors. One of the most persistent challenges is the "healthy vaccine bias," a phenomenon where individuals who choose to get vaccinated might already be healthier or have better access to healthcare than those who do not. The Oxford team recognized this critical limitation in previous studies and designed their research specifically to address it.
n
Beyond Observation: The Natural Experiment
n
The core challenge for the researchers was to move beyond simple correlation and closer to inferring causation. "Were people getting vaccinated against shingles healthier to begin with than those who weren’t vaccinated? Did their better access to health care, as evidenced by their inoculations, better protect them from the disease?" these were the critical questions the Oxford team aimed to answer. To overcome the healthy vaccine bias, they devised an ingenious "natural experiment." This approach capitalized on a real-world event that effectively created two comparable groups for study.
n
The crucial event was the U.S. Food and Drug Administration’s approval of Shingrix in October 2017. This approval marked a significant turning point, as Shingrix rapidly replaced Zostavax, the older live-attenuated shingles vaccine, as the preferred option. By comparing similar groups of vaccinated individuals immediately before and immediately after this regulatory shift, the researchers could minimize the impact of inherent health differences between vaccinated and unvaccinated populations. This method allowed them to compare the effects of two different vaccines (Zostavax vs. Shingrix) on populations that were, by virtue of their shared decision to get vaccinated around the same time, likely to be more similar in terms of health-seeking behaviors and overall health status.
n
Methodology: A Tale of Two Vaccines
n
The study, published in Nature Medicine, meticulously analyzed electronic health records (EHRs) from the TriNetX network, a vast database encompassing data from 60 health systems across the United States. The researchers focused on 72,000 vaccinated individuals aged 60 and older. To create their matched comparison groups, they identified two cohorts: one group received the Zostavax vaccine within six months before Shingrix’s U.S. approval in October 2017, and the other group received the Shingrix vaccine within six months after its approval. This design ensured that both groups consisted of individuals who had made the proactive decision to get vaccinated against shingles, thus largely controlling for the "healthy vaccine bias." It’s important to note that the TriNetX network primarily captures data from individuals with private health insurance, meaning the study population does not include those relying solely on public health insurance.
n
The researchers then followed these two matched groups for seven years, carefully tracking the incidence of various cardiovascular events. By comparing the rates of these events between the Zostavax and Shingrix cohorts, they could isolate the potential differential effects of the newer vaccine. This rigorous methodology allowed the team to draw more confident conclusions about the associations observed, providing a stronger foundation for the emerging understanding of Shingrix’s broader health impacts.
n
Quantifying the Cardioprotective Effect
n
The results of this seven-year follow-up study were compelling, revealing a consistent pattern of reduced cardiovascular risk among those who received the Shingrix vaccine compared to the older Zostavax.
n
Significant Reductions Across the Board
n
After seven years of follow-up, the study found that receiving Shingrix, as opposed to Zostavax, was associated with a 9% lower overall cardiovascular burden. This "burden" was broadly defined to include a critical bucket of serious cardiovascular events: coronary heart disease, heart failure, and stroke. Delving deeper into the specific conditions, the data showed even more granular benefits:
n
- n
- Coronary heart disease was reduced by an impressive 10% in the Shingrix cohort.
- Heart failure saw a 12% reduction.
- Strokes were significantly down by 12% in men, though a statistically significant reduction was not observed in women in this particular study.
- Atrial fibrillation, a common heart rhythm disorder, was also 7% lower in all vaccinated individuals receiving Shingrix.
n
n
n
n
n
While these percentages represent relative risk reductions, which can appear substantial, the researchers also provided the absolute terms: a 1% fewer cardiovascular events after seven years for individuals receiving Shingrix. Although this absolute figure might seem modest on an individual level, its implications become profound when considered at a population scale.
n
Population-Level Impact
n
Mark Russell, a clinical senior lecturer and consultant rheumatologist at King’s College London, underscored the broader significance of these findings. "Although the benefits are relatively small on an individual basis, millions of people receive shingles vaccination, meaning that even a small cardiovascular benefit could translate into a substantial number of cardiovascular events prevented at a population level," Russell stated in a release shared by the Science Media Centre. His comments highlight a crucial aspect of public health interventions: even marginal individual gains can accumulate into massive collective benefits when applied across large populations.
Maxime Taquet, an associate professor of psychiatry at the University of Oxford and a co-author of the study, echoed this sentiment, emphasizing the potential for widespread impact. "If confirmed, Shingrix could prevent hundreds of thousands of cardiovascular events in the USA alone, and may be the first vaccine that protects the heart and the brain," Taquet remarked. This vision of a vaccine offering dual protection against two of the most prevalent and debilitating chronic conditions—dementia and heart disease—underscores the transformative potential of these findings. The economic and societal burden of these diseases is immense, making any effective preventive strategy, however small its individual effect, a game-changer for healthcare systems globally.
Expert Perspectives and Future Directions
The scientific community has reacted to these findings with a blend of excitement and cautious optimism, emphasizing the need for further rigorous investigation while acknowledging the significance of the current data.
Cautious Optimism from Leading Researchers
Kaleen Hayes, associate director of pharmacoepidemiology at Brown University School of Public Health, whose own research includes studies on dementia risk after Shingrix vaccination, expressed considerable enthusiasm. "This was really the next question everyone was wondering about," Hayes told STAT in an interview, though she was not involved in the Nature Medicine study. She acknowledged the conflicting evidence that had existed previously regarding the vaccine’s cardioprotective and neuroprotective effects. "There’s been some evidence, but very conflicting evidence on whether this vaccine has cardioprotective effects as well as potential neuroprotective effects," she noted, underscoring the importance of the Oxford team’s latest contribution in clarifying these signals.
The study authors themselves, while encouraged by the results, maintained a professional and measured tone. They openly acknowledged the inherent limitations of even a meticulously designed observational study.
The Call for Randomized Controlled Trials
Maxime Taquet, co-author of the study, articulated the scientific imperative for further validation. "This study remains observational, even though it’s a natural experiment, and so we are keen to see results from randomized controlled trials. And one of them is underway," he stated at a media briefing. This commitment to rigorous follow-up reflects the highest standards of scientific inquiry. Randomized controlled trials (RCTs) are considered the gold standard for establishing cause and effect, as they eliminate biases more effectively than observational studies.
Taquet was referring to the DAN ZOSTER study (NCT07485283), an ambitious research effort involving approximately 162,000 people in Denmark. This large-scale RCT is specifically designed to investigate the potential cardiovascular benefits of shingles vaccination in a controlled setting. The scientific community eagerly awaits its first results, which are anticipated in 2027. The outcomes of DAN ZOSTER will be critical in confirming, or refuting, the associations observed in the Oxford team’s observational work, providing definitive evidence on whether Shingrix truly offers direct cardioprotection.
Broader Implications for Public Health
If the findings from the Oxford study are indeed confirmed by randomized controlled trials, the implications for public health could be profound. A vaccine that not only prevents a painful viral disease but also reduces the risk of two major chronic conditions – dementia and heart disease – would represent a significant paradigm shift in preventive medicine. Such a tool could dramatically reduce the burden on healthcare systems and improve the quality of life for millions of older adults.
The potential for Shingrix to become a cornerstone of comprehensive health maintenance for an aging global population is immense. This expanded understanding of its benefits could lead to reconsiderations of vaccination guidelines, potentially encouraging higher uptake rates and even exploring its utility in broader demographics.
Unraveling the Mechanism: How Shingrix Might Protect the Heart
While the observational study provides strong evidence of an association, the exact biological mechanism by which Shingrix might confer cardioprotection remains a subject of ongoing scientific inquiry and speculation. The researchers offered several hypotheses, delving into the unique properties of the vaccine and its interaction with the immune system.
The Role of the Herpes Virus and Inflammation
One leading hypothesis centers on the herpes zoster virus itself, the causative agent of shingles. Research has consistently shown that acute herpes zoster infection can heighten the risk of cardiovascular disease. The virus triggers a significant inflammatory response in the body, and this systemic inflammation is known to contribute to endothelial dysfunction, plaque instability, and the progression of atherosclerosis – the underlying process of most cardiovascular diseases.
Therefore, one plausible explanation is that Shingrix, being significantly more effective at preventing shingles than its predecessor Zostavax, simply offers superior protection against the inflammatory cascade initiated by the reactivated virus. By preventing shingles, it prevents the subsequent inflammation and vascular damage that could otherwise lead to cardiovascular events. This direct protective effect against the primary infection would naturally translate into a reduced risk of its downstream complications, including heart disease.
Trained Immunity and the AS01 Adjuvant
However, the researchers also suggested a more nuanced and potentially groundbreaking mechanism related to Shingrix’s unique composition. They speculated that the vaccine might induce "trained immunity," a concept that describes long-lasting changes in innate immune cells that lead to an enhanced, non-specific response to subsequent infections.
Fabiana Corsi-Zuelli, a research fellow in Psychiatry at Oxford and a co-author, explained: "The recombinant vaccine may induce trained immunity. That means changes in cells of our immune system." These changes are distinct from the highly specific adaptive immunity (antibody production) typically associated with vaccines. Trained immunity involves epigenetic modifications to innate immune cells, making them more responsive to future threats.
A key player in this proposed mechanism is the AS01 adjuvant, a chemical component added to Shingrix but not to Zostavax. Adjuvants are substances included in vaccines to enhance the immune response. Taquet pointed directly to AS01 as a potential driver of the observed cardiovascular benefits. "For cardiovascular disease in particular, we’ve got a bit more stronger hypothesis that this has to do with the adjuvant, because we haven’t seen any protection of Zostavax vaccines for cardiovascular disease, and the natural experiments have not found any effect on cardiovascular outcome," he emphasized. The absence of similar cardiovascular benefits with Zostavax, which lacks AS01, strongly suggests that this adjuvant, or the specific type of immune response it elicits, is critical.
Betty Raman, associate professor of cardiovascular medicine at Oxford and a study co-author, elaborated on how these immune changes could impact cardiovascular health. "Ischemic heart disease and vascular diseases tend to be linked to an inflammatory response," Raman explained. "So the cytokines essentially activate cells within the tissue that can promote atherosclerosis, which is basically deposition of fat in the wall, and that in turn can lead to vascular events like a blockage in the arteries." The "trained immunity" induced by Shingrix, potentially via AS01, might modulate the production of cytokines – proteins that regulate immune and inflammatory responses – thereby dampening systemic inflammation and reducing the progression of atherosclerosis. This anti-inflammatory effect could be a direct pathway to cardiovascular protection.
Brown’s Kaleen Hayes also weighed in on the mechanistic debate, suggesting that the vaccine’s robust immune response to shingles, whether specifically tied to AS01 or a general heightened immunity, could play a role in moderating inflammation risk. "Whether it’s the actual AS01 versus just in general, it’s an effective vaccine and our immune system gets keyed up is, I think, very much still on the table as to what’s the potentially right answer here," she said. Hayes also highlighted the broader implications for drug discovery: "Being able to harness what we can learn from the benefits to understand our options for new therapeutics in this area — I think that will be a really exciting field that’s to come."
From Speculation to Prevention: The Road Ahead
The Oxford team’s findings, while necessitating further confirmation, open up exciting new avenues for public health and preventive medicine. The potential for Shingrix to offer benefits beyond shingles prevention has significant implications for vaccination strategies and future research.
Expanding the Scope of Vaccination
Currently, shingles vaccines are recommended primarily for middle-aged and older adults, the demographic most susceptible to the disease and its severe complications. However, if the broader cardiovascular and neuroprotective effects of Shingrix are definitively proven, the question arises whether other populations could also benefit. Oxford’s Betty Raman called for more research and randomized control trials to "define the right population to treat," suggesting that the scope of Shingrix administration might eventually be expanded. This could include younger individuals who might be at higher risk for certain cardiovascular conditions or who could benefit from long-term preventive strategies against both heart disease and dementia.
Expanding vaccination guidelines would require careful consideration of cost-effectiveness, vaccine supply, and the overall public health benefit-risk profile for different age groups. However, the potential to leverage an existing, safe, and effective vaccine for multiple major health challenges is an enticing prospect for policymakers and healthcare providers.
A Potential Paradigm Shift in Preventive Medicine
Maxime Taquet expressed his hope that these findings would encourage more people to get vaccinated against shingles, not just for the immediate protection against the painful viral infection, but also for the promising secondary benefits. "If these findings and the findings we provided for dementia help sort of nudge that, then that’s great. And if they are then confirmed in randomized controlled trials, the benefit might be enormous, for the people and for the economy and the health services," he affirmed.
Taquet concluded with a clear message: "If this helps people get the vaccine, then that’s great. But they should get it for the shingles protection in the first instance." This underscores the vaccine’s primary, proven benefit while highlighting the exciting potential for its role in a broader preventive health strategy.
The journey from preventing a painful rash to potentially safeguarding the heart and brain is a testament to the unforeseen discoveries that can emerge from rigorous scientific inquiry. As the scientific community awaits the definitive answers from randomized controlled trials like DAN ZOSTER, the Shingrix vaccine stands as a compelling example of how a deeper understanding of our immune system and viral interactions can unlock transformative possibilities for human health. If confirmed, Shingrix could indeed mark a new era in preventive medicine, offering a single intervention with profound, multi-systemic benefits.
STAT’s coverage of chronic health issues is supported by a grant from Bloomberg Philanthropies. Our financial supporters are not involved in any decisions about our journalism.
